Sight Sciences, Inc. reported its financial results for the fiscal year ending December 31, 2025, revealing a total revenue of $77.4 million, a decrease of 3.1% from $79.9 million in 2024. The company's Interventional Glaucoma segment generated $75.7 million, slightly down from $75.9 million the previous year, primarily due to changes in reimbursement coverage and increased competition in the minimally invasive glaucoma surgery (MIGS) market. Conversely, revenue from the Interventional Dry Eye segment fell significantly by 58.7% to $1.6 million, attributed to a strategic shift towards establishing reimbursement for the TearCare procedure, which is designed to treat meibomian gland disease (MGD).
The company's gross profit for 2025 was $66.7 million, down from $68.3 million in 2024, with an overall gross margin of 86.2%, an increase from 85.5% the previous year. The Interventional Glaucoma segment's gross margin decreased to 86.8%, while the Interventional Dry Eye segment saw an improvement to 59.3%, reflecting higher average selling prices. Operating expenses decreased by 12.7% to $103.8 million, driven by reductions in research and development and selling, general, and administrative costs, largely due to a workforce reduction implemented in August 2025.
Sight Sciences continues to focus on expanding its market presence, particularly for its TearCare product, which has recently seen improved reimbursement coverage from two Medicare Administrative Contractors (MACs). The company is also working to establish OMNI and SION as standards of care in the glaucoma treatment space. As of December 31, 2025, the company had cash and cash equivalents of $92.0 million, with an accumulated deficit of $384.7 million, indicating ongoing financial challenges as it seeks to achieve profitability.
Looking ahead, Sight Sciences anticipates continued investment in clinical trials and product development to enhance its offerings and capture market share. The company is also expanding its manufacturing capabilities outside of China to mitigate risks associated with geopolitical tensions and tariffs that have impacted its cost structure. Despite the challenges, management remains optimistic about the potential for growth in both the Interventional Glaucoma and Interventional Dry Eye segments, contingent on successful reimbursement strategies and market education efforts.
About Sight Sciences, Inc.
Sight Sciences, Inc. develops interventional ophthalmic technologies targeting prevalent eye diseases like glaucoma and dry eye. Its core products include MIGS devices (OMNI, SION) for glaucoma and TearCare for dry eye, used by eye care professionals worldwide. The company's solutions focus on restoring natural eye function through evidence-based, minimally invasive procedures, emphasizing clinical efficacy, patient comfort, and market access to improve patient outcomes.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.